A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)
Latest Information Update: 10 Feb 2025
At a glance
- Drugs Cretostimogene grenadenorepvec (Primary) ; Nivolumab (Primary) ; Anti-CTLA-4 monoclonal antibody
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CORE2; NAOMI
- 06 Feb 2025 Planned End Date changed from 1 Feb 2025 to 1 Jan 2026.
- 11 Nov 2024 Results presented in the CG Oncolgy Media Release.
- 11 Nov 2024 According to a CG Oncolgy media release, Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024.